Salud financiera de hoja de balance de Alvotech

Salud financiera controles de criterios 0/6

Alvotech tiene un patrimonio de los accionistas total de $-932.5M y una deuda total de $960.2M, lo que sitúa su ratio deuda-patrimonio en -103%. Sus activos y pasivos totales son $950.1M y $1.9B respectivamente.

Información clave

-103.0%

Ratio deuda-patrimonio

US$960.16m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$11.16m
Patrimonio	-US$932.49m
Total pasivo	US$1.88b
Activos totales	US$950.09m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Alvotech: Consider Buying As Positive Q1 Earnings Release Likely

Apr 25

Alvotech (NASDAQ:ALVO) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Apr 03

Alvotech (NASDAQ:ALVO) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 24

Analysts Just Shaved Their Alvotech (NASDAQ:ALVO) Forecasts Dramatically

Sep 03

Positive Sentiment Still Eludes Alvotech (NASDAQ:ALVO) Following 27% Share Price Slump

May 05

Shareholders Shouldn’t Be Too Comfortable With Alvotech's (NASDAQ:ALVO) Strong Earnings

Nov 23

Alvotech starts pharmacokinetic study for its biosimilar to Amgen's bone disease drugs

Jul 20

Icelandic biosimilars developer Alvotech initiated with a hold rating by Deutsche Bank

Jul 01

Análisis de la situación financiera

Pasivos a corto plazo: ALVO tiene patrimonio neto negativo. Es una situación más grave que activos a corto plazo que no cubren pasivos a corto plazo.

Pasivo a largo plazo: ALVO tiene patrimonio neto negativo. Esta situación es más grave que el hecho de que los activos a corto plazo no cubran los pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: ALVO tiene patrimonio negativo, una situación más grave que un alto nivel de endeudamiento.

Reducción de la deuda: ALVO tiene patrimonio neto negativo, por lo que no necesitamos comprobar si su deuda se ha reducido con el tiempo.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ALVO tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: Datos insuficientes para determinar si ALVO tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.

Salud financiera de hoja de balance de Alvotech

Salud financiera controles de criterios 0/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Alvotech: Consider Buying As Positive Q1 Earnings Release Likely

Alvotech Announces Topline Results from A Confirmatory Clinical Study for AVT05, A Proposed Biosimilar for Simponi (Golimumab)

Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)

Alvotech (NASDAQ:ALVO) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Consensus EPS estimates fall by 28%, revenue upgraded

Price target increased by 10% to US$16.17

Alvotech (NASDAQ:ALVO) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

Alvotech Announces Executive Changes

Price target increased by 9.6% to US$12.33

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva

Alvotech Provides Update on Status of Biologics License Applications for Avt02 and Avt04

STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara

Consensus revenue estimates increase by 45%

Consensus revenue estimates decrease by 41%, EPS upgraded

New major risk - Financial position

Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.04 loss in 3Q 2022)

Alvotech Announces Positive Top-Line Results from A Pharmacokinetic Study for Avt05

Light Curve Capital Holdings Pte. Ltd made an offer to acquire Alvotech Hannover Gmbh from Alvotech (NasdaqGM:ALVO).

STADA and Alvotech Receive Positive CHMP Opinion for Europe's First Ustekinumab Biosimilar to Stelara

Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04

Price target decreased by 25% to US$8.10

Alvotech Announces Approval in Japan of Avt04 (Ustekinumab), A Biosimilar to Stelara®

Alvotech Announces U.S. Food and Drug Administration Accepts its Resubmitted Biologics License Application (BLA) for AVT02

Alvotech Announces Changes to the Leadership Team

Consensus revenue estimates fall by 26%

Analysts Just Shaved Their Alvotech (NASDAQ:ALVO) Forecasts Dramatically

Forecast breakeven date pushed back to 2025

Second quarter 2023 earnings released: EPS: US$0.85 (vs US$0.58 loss in 2Q 2022)

Alvotech and Bioventure Announces Approval of AVT02 (Adalimumab) in Egypt

Alvotech announced that it expects to receive $40 million in funding from Teva Pharmaceutical Industries Limited

Alvotech to Report Q3, 2023 Results on Nov 14, 2023

Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02

New minor risk - Share price stability

Consensus revenue estimates decrease by 15%, EPS upgraded

Forecast breakeven date moved forward to 2024

Price target decreased by 8.8% to US$12.40

First quarter 2023 earnings released: US$1.24 loss per share (vs US$0.51 loss in 1Q 2022)

Alvotech, Annual General Meeting, Jun 06, 2023

Alvotech Initiates Confirmatory Patient Study for AVT05, Proposed Biosimilar for Simponi and Simponi Aria

Positive Sentiment Still Eludes Alvotech (NASDAQ:ALVO) Following 27% Share Price Slump

Alvotech to Report Q1, 2023 Results on May 18, 2023

Consensus revenue estimates increase by 10%

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: EPS and revenues miss analyst expectations

European Medicines Agency Accepts a Marketing Authorization Application for AVT04 of Alvotech

Alvotech Announces European Medicines Agency (EMA) Accepts Marketing Authorization Application for AVT04

Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia

Alvotech Initiates Pharmacokinetic Study for AVT05

Alvotech and Teva Announces Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

Alvotech Announces FDA Grant A New Biosimilar User Fee Amendment

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Alvotech Announces Executive Changes, Effective January 1, 2023

Consensus EPS estimates fall by 12%

Shareholders Shouldn’t Be Too Comfortable With Alvotech's (NASDAQ:ALVO) Strong Earnings

Alvotech announced that it has received $50 million in funding from Alvogen, Inc.

Alvotech announced that it has received $50 million in funding from Alvogen, Inc.

Third quarter 2022 earnings released

Less than half of directors are independent

Alvotech Announces Australian Marketing Authorization for AVT02, A Biosimilar to Humira

Alvotech to Report Nine Months, 2022 Results on Nov 15, 2022

Fuji Pharma files for approval of biosimilar candidate in Japan

Alvotech Announces Executive Changes

Consensus forecasts updated

Alvotech and STADA Increase Access to Adalimumab for Patients in Switzerland with the Launch of Hukyndra®

Alvotech and STADA launch Humira biosimilar in Switzerland

Consensus forecasts updated

Alvotech Reports Update on Initial AVT02 Biologics License Application

Alvotech Reports Update on Initial AVT02 Biologics License Application

First half 2022 earnings released

Alvotech GAAP EPS of -$1.02, revenue of $40.1M

Alvotech Initiates Confirmatory Patient Study for Avt03, A Proposed Biosimilar for Prolia® and Xgeva®

Alvotech to Report Q2, 2022 Results on Aug 31, 2022